Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0470 • ACR Convergence 2024
New Approach for Early and Accurate Diagnosis of Rheumatoid Arthritis-related Interstitial Lung Disease: Matrix Metalloproteinases 7 and 9 as Novel Blood Biomarkers
Veronica Pulito-Cueto¹, Belén Atienza-Mateo², gonzalo Ocejo-Viñals³, Victor M. Mora-Cuesta⁴, David Iturbe-Fernández⁴, Joao Carlos Batista-Liz¹, María Sebastián Mora-Gil⁵, Mónica Renuncio-García⁶, Elena González López³, José M. Cifrián⁷, Ricardo Blanco-Alonso⁸ and Raquel Lopez-mejias¹, ¹IDIVAL, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ³Department of Immunology, Marqués de Valdecilla University Hospital (HUMV), Santander, Spain, ⁴Immunopathology Group, Valdecilla Research Institute (IDIVAL) and Department of Pneumology, Marqués de Valdecilla University Hospital (HUMV), Santander, ⁵Immunopathology Group, Valdecilla Research Institute (IDIVAL) and Department of Rheumatology, Marqués de Valdecilla University Hospital (HUMV), Santander, ⁶Division of Immunology, Hospital Universitario Marqués de Valdecilla, Immunopathology Group, IDIVAL, Santander, Spain, ⁷Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. Immunopathology group, IDIVAL, Santander, ⁸Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is one of the main causes of death in rheumatoid arthritis (RA) patients [1]. Early diagnosis of RA-ILD+ is critical…
Abstract Number: 0487 • ACR Convergence 2024
The Triglyceride to HDL Ratio, a Surrogate Marker of Insulin Resistance, Predicts All Cause and Cardiovascular Mortality in Rheumatoid Arthritis
Jose Felix Restrepo Suarez¹, Carlos Lorenzo¹, Inmaculada Del rincon² and Agustin Escalante¹, ¹UT Health San Antonio, San Antonio, TX, ²UT Health San Antonio, San Antonio
Background/Purpose: The triglyceride to HDL cholesterol (TG/HDL) ratio, a recognized surrogate marker of insulin resistance, has emerged as a predictor of cardiovascular (CV) risk. However,…
Abstract Number: 0504 • ACR Convergence 2024
Janus Kinase Inhibitors Persist Longer Than Biologics in Rheumatoid Arthritis: Retrospective Analysis of Real-world Outpatient Data from the German Rhadar Database
Linus Maximilian Risser¹, Torsten Witte², Matthias Englbrecht³, Patrick-Pascal Strunz⁴, Matthias Froehlich⁵, Marc Schmalzing⁶, Michael Gernert⁷, Peter Bartz-Bazzanella⁸, Cay von Der Decken⁹, Kirsten Karberg¹⁰, Georg Gauler¹¹, Susanna Spaethling-Mestekemper¹², Christoph Kuhn¹³, Wolfgang Vorbrueggen¹⁴, Martin Welcker¹⁵ and Stefan Kleinert¹⁶, ¹Hannover Medical School, Hannover, Germany, ²Dept of Immunology and Rheumatology, Hannover, Germany, ³Freelance Healthcare Data Scientist, Eckental, ⁴University hospital of Wuerzburg, Wuerzburg, Germany, ⁵Uniklinikum Wuerzburg, Medizinische Klinik II, Wuerzburg, Germany, ⁶University Hospital Wuerzburg, Würzburg, Germany, ⁷Medicine II, Division Rheumatology/Clinical Immunology, University Hospital of Wuerzburg, Wuerzburg, ⁸Rhein-Maas Klinikum, Wuerselen, Germany, ⁹Klinik für Internistische Rheumatologie, Rhein-Maas-Klinik Wuerselen, Würselen, ¹⁰Rheumatologisches Versorgungszentrum Steglitz, Berlin, Germany, ¹¹rheumapraxis, Osnabrück, Germany, ¹²Rheumapraxis Muenchen, Muenchen, Germany, ¹³Praxis für Rheumatologie, Karlsruhe, Germany, ¹⁴Verein zur Foerderung der Rheumatologie e.V, Wuerselen, Germany, ¹⁵Medizinisches Versorgungszentrum für Rheumatologie Dr. M. Welcker GmbH, Planegg, Germany, ¹⁶Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany
Background/Purpose: Numerous biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) have been approved for treating rheumatoid arthritis (RA), including Janus kinase inhibitors (JAKi), rituximab, abatacept,…
Abstract Number: 0521 • ACR Convergence 2024
Transcriptome Analysis of Drug Response in a Large Cohort of Immune-Mediated Inflammatory Disease Patients Supports Advanced Combination Therapy in Rheumatoid Arthritis
Ernest Choy¹, Maria López Lasanta², Paloma Vela-Casasempere³, Antonio Fernandez Nebro⁴, Santos Castañeda⁵, Carlos Marras⁶, Jaime Calvo-Alén⁷, Jesus Tornero⁸, Juan Cañete⁹, Eugeni Domènech¹⁰, Javier Gisbert¹¹, José Manuel Carrascosa¹², Eduardo Fonseca¹³, Luis Bujanda¹⁴, Valle García¹⁵, Britta Siegmund¹⁶, Giampiero Girolomoni¹⁷, Holger Heyn¹⁸, Pere Santamaria¹⁹, Richard M Myers²⁰, yolanda Guillen²¹, Sergio H Martínez-Mateu²², Sara Marsal²³ and Antonio Julia²⁴, and IMID Consortium, ¹Cardiff University School of Medicine, Cardiff, United Kingdom, ²Hospital Universitari Vall d´Hebron, Rheumatology, Barcelona, Spain, ³Hospital General Universitario Alicante, Alicante, Spain, ⁴Hospital Regional Universitario Carlos Haya , Rheumatology, Málaga, Spain, ⁵Hospital Universitario de la Princesa, Madrid, Spain, ⁶Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Murcia, Spain, ⁷Department of Rheumatology, Hospital Araba, Vitoria, Pais Vasco, Spain, ⁸Hospital Universitario de Guadalajara, Guadalajara, Spain, ⁹Hospital Clinic an IDIBAPS, Barcelona, Spain, ¹⁰Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ¹¹Hospital Universitario de la Princesa and IIS-IP, Madrid, Spain, ¹²Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹³Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ¹⁴Hospital Universitario de Donostia, San Sebastián, Spain, ¹⁵Hospital Universitario Reina Sofía, Córdoba, Spain, ¹⁶Charité – Universitätsmedizin Berlin, Berlin, Germany, ¹⁷University of Verona, Verona, Italy, ¹⁸Centre for Genomic Regulation (CNAG-CRG), National Centre for Genomic Analysis, Barcelona, Spain, ¹⁹Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ²⁰HudsonAlpha Institute for Biotechnology, Huntsville, AL, ²¹Imidomics, Inc, Barcelona, Spain, ²²IMIDOMICs, Barcelona, Spain, ²³Vall Hebron Hospital Research Institute, Barcelona, Spain, ²⁴Vall d'Hebron Hospital Research Institute, Barcelona, Spain
Background/Purpose: Targeted therapies have failed to provide sustained disease remission in most patients suffering from immune-mediated inflammatory diseases (IMIDs). Combining existing drugs could overcome this…
Abstract Number: 0538 • ACR Convergence 2024
Factors Associated with Upadacitinib Persistence and Risk Minimization Measures in Patients with Rheumatic Diseases in a Real-world Setting. UPAreal Study
Alicia Garcia Dorta¹, Cristina Rodríguez-Regalado², Andrea Hernández-Martín³, Sonia Peña-Montelongo⁴, Cristina Martínez-González¹, Elena Naveda-González⁵, Enrique González-Dávila⁶, Federico Diaz-González⁷ and Vanesa Hernández-Hernández⁸, ¹Hospital Universitario de Canarias, San Cristobal de La Laguna, Spain, ²Hospital Universitario Ntra Sra de la Candelaria, Santa Cruz de Tenerife, Spain, ³Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas, Spain, ⁴Hospital Virgen de la Peña, Fuerteventura, Spain, ⁵Hospital Universitario Dr Negrín, Las Palmas de Gran Canaria, Spain, ⁶Departamento de Matemáticas, Estadística e Investigación Operativa, Universidad La Laguna, San Cristobal de La Laguna, Spain, ⁷Hospital Universitario de Canarias, La Laguna, Spain, ⁸Hospital Universitario de Canarias, San Cristobal de La Laguna, Canarias, Spain
Background/Purpose: Upadacitinib (UPA), a Janus kinase inhibitor (JAKi) with three years of market experience, has not yet been the subject of a significant number of…
Abstract Number: 0869 • ACR Convergence 2024
Deciphering Pathogenic Phenotypes by Multi-modal Deep Single-cell Blood Immunophenotyping in Individuals At-risk for Rheumatoid Arthritis
Jun Inamo¹, Joshua Keegan², Alec Griffith², Tusharkanti Ghosh¹, Alice Horisberger², Kaitlyn Howard², John Pulford², Ekaterina Murzin², Brandon Hancock², Thomas Eisenhaure³, Salina Dominguez⁴, Miranda Gurra⁵, Siddarth Gurajala³, Anna Helena Jonsson¹, Jennifer Seifert⁶, Marie Feser⁷, Jill Norris⁸, Ye Cao², William Apruzzese⁹, S. Louis Bridges¹⁰, Vivian Bykerk¹¹, Susan Goodman¹², Laura Donlin¹¹, Gary S. Firestein¹³, Joan Bathon¹⁴, Laura B. Hughes¹⁵, Darren Tabechian¹⁶, Andrew Filer¹⁷, Costantino Pitzalis¹⁸, Jennifer Anolik¹⁹, Larry Moreland²⁰, Nir Hacohen²¹, Joel Guthridge²², Judith James²², Carla Cuda⁵, Harris Perlman⁵, Michael B. Brenner², Soumya Raychaudhuri²³, Jeffrey Sparks²⁴, Michael Holers⁷, Kevin Deane²⁵, James A. Lederer²⁶, Deepak Rao²⁶ and Fan Zhang²⁷, and the Accelerating Medicines Partnership RA/SLE Network, ¹University of Colorado School of Medicine, Aurora, CO, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Broad Institute of MIT and Harvard, Cambridge, ⁴Northwestern University, Chicago, ⁵Northwestern University, Chicago, IL, ⁶University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, ⁷Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁸Colorado School of Public Health, Denver, CO, ⁹Accelerating Medicines Partnership® Program: Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP® RA/SLE) Network, Boston, MA, ¹⁰Division of Rheumatology, Weill Cornell Medical College, New York, NY, ¹¹Hospital For Special Surgery, New York, NY, ¹²Hospital for Special Surgery, New York 10025, NY, ¹³University of California, San Diego, La Jolla, ¹⁴Columbia University, New York, NY, ¹⁵University of Alabama at Birmingham Medicine, Birmingham, AL, ¹⁶University of Rochester Medical Center, Rochester, ¹⁷Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Birmingham, United Kingdom, ¹⁸QMUL, Bromley Kent, United Kingdom, ¹⁹University of Rochester Medical Center, Rochester, NY, ²⁰University of Colorado, Denver, CO, ²¹Broad Institute of MIT and Harvard, Boston, MA, ²²Oklahoma Medical Research Foundation, Oklahoma City, OK, ²³Brigham and Women's Hospital, Boston, MA, ²⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ²⁵University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ²⁶Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²⁷University of Colorado, Aurora, CO
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease with currently no effective prevention strategies. Single-cell technologies have been recently used to investigate established RA…
Abstract Number: 0933 • ACR Convergence 2024
NLRP3 Inflammasome Promotes Release of Peptidyl Arginine Deiminases2 and 4 from Human Neutrophils
Teneema Kuriakose, Mingxin Yang, Lacie Scaletta and Gary Sims, Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD
Background/Purpose: Autoantibodies targeting citrullinated proteins (ACPAs) are a characteristic feature and a diagnostic marker in rheumatoid arthritis (RA). The generation of citrullinated protein autoantigens is…
Abstract Number: 0980 • ACR Convergence 2024
Ambient Air Pollution and Initiation of bDMARDs in Newly Diagnosed Rheumatoid Arthritis: A Nested Case-Control Study of NIH All of Us Cohort
Jiayi Zheng¹, Nevena Barjaktarovic² and Liangjing lu³, ¹Washington University School of Medicine, St. Louis, MO, ²The Wright Center for Community Health, South Abington Township, PA, ³Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic)
Background/Purpose: Ambient air pollution is a mixture of solid particles and gaseous pollutants derived from fossil fuel combustion and vehicle exhaust. Previous research has linked…
Abstract Number: 1037 • ACR Convergence 2024
Recommendations for the Perioperative Use of DMARDs in Rheumatic Diseases: A Scoping Review
Alice Terrett¹, Athena Chin², Mihye Kwon³, Samuel Whittle⁴ and Catherine Hill⁵, ¹The Queen Elizabeth Hospital, Adelaide, Australia, ²Royal Adelaide Hospital, Tranmere, South Australia, Australia, ³Konyang University, College of Medicine, Daejeon, Republic of Korea, ⁴The Queen Elizabeth Hospital, Springfield, South Australia, Australia, ⁵The Queen Elizabeth Hospital, Woodville, South Australia, Australia
Background/Purpose: The use of disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of autoimmune rheumatic diseases, including rheumatoid arthritis (RA), has significantly improved disease and functional…
Abstract Number: 1246 • ACR Convergence 2024
Long-Term Outcomes Based on the Sex of the Rheumatologist in a Prospective Cohort of RA Patients Receiving Biological Therapies
Alessandro Giollo¹, Mariangela Salvato², Margherita Zen³ and doria Andrea⁴, ¹Azienda Ospedale Università Padova, Padova, Padua, Italy, ²University of Padua, Padova, Italy, ³University of Padova, Padova, Padua, Italy, ⁴University of Padova, Padova, Italy
Background/Purpose: To explore the influence of the rheumatologist's sex on long-term outcomes in patients with rheumatoid arthritis (RA) undergoing biologic therapy.Methods: This is a prospective,…
Abstract Number: 1336 • ACR Convergence 2024
Risk of Malignancy Under the Treatments with Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: An Analysis Using Japanese Health Insurance Database
Ryoko Sakai¹, Eiichi Tanaka², Eisuke Inoue³ and Masayoshi Harigai⁴, ¹Meiji Pharmaceutical University, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ³Showa University, Tokyo, Japan, ⁴Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Janus kinase inhibitors (JAKIs) have shown positive therapeutic impacts on treatments for rheumatoid arthritis (RA), whereas, there are concerns about the risk of malignancy…
Abstract Number: 1352 • ACR Convergence 2024
The Associations Between Genetic Factors and Rheumatoid Arthritis Treatment Patterns: Data from Two Large Healthcare Systems
Gregory McDermott¹, Xin Xiong², Rachel Knevel³, Jing Cui⁴, Mary Jeffway⁴, Vidul Panickan⁵, Andrew Cagan⁴, Rahul Sangar⁶, Daniel Posner⁶, Lauren Costa⁶, Rachael Matty⁶, Elizabeth Karlson⁴, Yuk-Lam Ho⁶, Kelly Cho⁶, Rui Duan², Tianxi Cai² and Katherine Liao⁴, ¹Brigham and Women's Hospital, Brookline, MA, ²Harvard T.H. Chan School of Public Health, Boston, MA, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Harvard Medical School, Boston, MA, ⁶U.S. Department of Veterans Affairs, Boston, MA
Background/Purpose: In a prior study, we described an alternative method for subphenotyping RA patients by the sequence of biologic DMARDs (bDMARDs) they receive over time.…
Abstract Number: 1368 • ACR Convergence 2024
Do CsDMARDs Still Play a Significant Role in Managing Rheumatoid Arthritis in the Current Biologic/JAKI Era? A Prospective Observational Study to Estimate the Extent of Response to Conventional Synthetic DMARDs in RA– Experience from a Tertiary Care Center in South India
Prabhu Vasanth¹, John Mathew² and Divya K³, ¹Christian Medical college , Vellore , India, Vellore, Tamil Nadu, India, ²Christian Medical college , Vellore , India, Vellore, India, ³Christian Medical College, Vellore, Tamil Nadu, India
Background/Purpose: Conventional synthetic DMARDs remained the mainstay of treatment of RA for decades. However, their use has decreased recently due to the emergence of biological…
Abstract Number: 1385 • ACR Convergence 2024
A Novel Oral 3D-Printed Delayed- and Extended-Release Tofacitinib (T19) for the Treatment of Rheumatoid Arthritis and Related Inflammatory Diseases
Yue Zhou, Meng Ji, luo wang, Feihuang Deng, Senping Cheng, Xiaoling Li and Yulian Zhang, Triastek, Inc., Nanjing, China (People's Republic)
Background/Purpose: Patients with inflammatory diseases, such as rheumatoid arthritis (RA), frequently continue to suffer from morning symptoms despite treatment with conventional therapies 1,2. Routine morning…
Abstract Number: 1401 • ACR Convergence 2024
Risk of Malignancy with TNF-α Inhibitors in Patients with Rheumatoid Arthritis
Omair Khan¹, Syed Mujtaba Baqir², Azka Naeem², Muhammad Hashim khan², Tharun Shyam², Kseniya Slobodyanyuk³ and Anastasia Slobodnick⁴, ¹Maimonides Medical Center, Council Bluffs, IA, ²Maimonides Medical Center, Brooklyn, NY, ³Maimonides Medical Center, Manhattan, NY, ⁴Northwell, Staten Island, NY
Background/Purpose: Rheumatoid arthritis (RA) is associated with various comorbidities and complications among which cancer has been highlighted in literature. This cancer risk has been attributed…

« Previous Page
1
…
6
7
8
9
10
…
188
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].